Rising Dementia Incidence Fuels Growth In Acute Agitation And Aggression Treatment Market: Key Factor Driving The Growth In The Acute Agitation And Aggression Treatment Market

The Acute Agitation And Aggression Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Projected Growth of the Acute Agitation And Aggression Treatment Market?
The acute agitation and aggression treatment market size has grown significantly in recent years. It will grow from $5.72 billion in 2024 to $6.05 billion in 2025, at a compound annual growth rate (CAGR) of 5.8%. The growth is due to advancements in pharmacology, increased clinical research, regulatory approvals, a rise in the prevalence of acute agitation and aggression cases, and greater awareness regarding mental health.

The acute agitation and aggression treatment market is anticipated to reach $7.77 billion in 2029, growing at a CAGR of 6.4%. Growth is supported by an aging demographic, expanding health systems, pharma investment, home care adoption, and higher incomes. Key trends are non-drug therapies, precision treatment, AI-based insights, community models, and industry alliances.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13078

What Are the Different Acute Agitation And Aggression Treatment Market Segments?
The acute agitation and aggression treatment market covered in this report is segmented -

1) By Treatment Approach: Behavioral Approaches, Environmental Interventions, Pharmacologic Approaches
2) By Drug Class: Anti-Psychotics, Benzodiazepines, Other Drug Classes
3) By Route of Administration: Oral, Intramuscular, Other Routes of Administrations
4) By Indication: Schizophrenia, Dementia, Bipolar Disorder, Depression, Drug-Induced Agitation And Aggression, Alcohol Withdrawal, Other Indications
5) By End User: Hospitals And Ambulatory Surgical Centers, Psychiatric Care Facilities, Other End Users

Subsegments:
1) By Box Style: Standard Box Action Cameras, Modular Box Action Cameras
2) By Cube Style: Compact Cube Action Cameras, Cube Cameras with Integrated Mounts
3) By Bullet Style: Long, Cylindrical Action Cameras, Mountable Bullet Cameras
4) By Periscope & 360°: 360-Degree Cameras, Periscope Cameras
5) By Other Types: Wearable Action Cameras, Drone Action Cameras, Specialty Action Cameras

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13078&type=smp

What Are the Primary Drivers Shaping the Acute Agitation And Aggression Treatment Market?
The growing occurrence of dementia is expected to drive the growth of the acute agitation and aggression treatment market. Dementia involves conditions that impair memory, cognition, and daily task management. Agitation, characterized by restlessness or repetitive actions, is a common symptom in dementia patients. Acute agitation and aggression treatments help reduce these harmful symptoms and enhance the patient's quality of life. For example, in February 2023, the Australian Institute of Health and Welfare estimated that around 401,300 Australians had dementia in 2022, with this number expected to double to 849,300 by 2058. This increase in dementia cases is boosting the growth of the treatment market.

Which Companies Are Leading in the Acute Agitation And Aggression Treatment Market?
Major companies operating in the acute agitation and aggression treatment market include Pfizer Inc., Johnson and Johnson Pvt Ltd., F Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Mylan NV, Biogen Inc., Bausch Health Companies Inc., UCB SA, Servier Laboratories, Sun Pharmaceutical Industries Ltd., AstraZeneca PLC, Ono Pharmaceutical Co Ltd., Apotex Inc., H Lundbeck A/S, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Neurocrine Biosciences Inc., Aurobindo Pharma Limited, Alkermes plc., Indivior plc., Sunovion Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., and Alexza Pharmaceuticals Inc

What Trends Are Driving Growth in The Acute Agitation And Aggression Treatment Market?
Companies in the acute agitation and aggression treatment market are working on developing innovative treatments, such as IGALMI (dexmedetomidine), to provide new options for patients with agitation linked to schizophrenia or bipolar disorder. IGALMI is a sublingual film that treats acute agitation associated with schizophrenia or bipolar disorder in adults. For instance, in April 2022, BioXcel Therapeutics Inc., a US-based biopharmaceutical company, received FDA approval for IGALMI, a quick-acting, short-duration treatment that can improve existing therapies for severe or life-threatening conditions.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/acute-agitation-and-aggression-treatment-global-market-report

What Are the Top Revenue-Generating Geographies in the Acute Agitation And Aggression Treatment Market?
The countries covered in the acute agitation and aggression treatment market market report include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Acute Agitation And Aggression Treatment Market?
2. What is the CAGR expected in the Acute Agitation And Aggression Treatment Market?
3. What Are the Key Innovations Transforming the Acute Agitation And Aggression Treatment Industry?
4. Which Region Is Leading the Acute Agitation And Aggression Treatment Market?

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.